XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.

Kurt A JenkinsMiso ParkMagali Pederzoli-RibeilUgur EskiocakParker JohnsonWilson GuzmanMegan McLaughlinDeborah Moore-LaiCaitlin O'TooleZhen LiuBenjamin NicholsonVeronica FleschHuawei QiuTim ClacksonRonan C O'HaganUlrich RodeckMargaret KarowJennifer O'NeilJohn C Williams

Published in: Journal for immunotherapy of cancer (2023)

These data demonstrate that XTX101 retains the full potency of an Fc-enhanced CTLA-4 antagonist within the TME while minimizing the activity in non-tumor tissue, supporting the further evaluation of XTX101 in clinical studies.

Keyphrases

monoclonal antibody
mouse model
papillary thyroid
squamous cell carcinoma
big data
electronic health record
artificial intelligence
young adults
squamous cell